Review



fluorescent proliferation tracking dye celltrace violet  (Thermo Fisher)


Bioz Verified Symbol Thermo Fisher is a verified supplier
Bioz Manufacturer Symbol Thermo Fisher manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Thermo Fisher fluorescent proliferation tracking dye celltrace violet
    (A-B) LCL growth in the presence of indicated doses of A939572 (SCD1i) (n = 4, LCLs from 4 donors). Growth was measured using Cell Titer Glo. (C-D) LCL growth in the presence of SC-26196 (FADS2i) (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (E) LCL growth in the presence of 10 μM SCD1i, 20 μM SC-26196 FADS2i, or both inhibitors (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (F) Representative dot plots, gated on live and dead single cells, showing anti-BrdU (FITC) versus total DNA (7-AAD) to measure the number of cells in each stage of the cell cycle at 48 hours post treatment. (G) DMSO-normalized relative percentage of single cells in S phase after 48 hours of drug treatment (n = 3, LCLs from 3 donors). (H) DMSO-normalized relative live cell percentage and number after 72 hours of treatment with indicated drugs (n = 4, from 4 donors). Cell number measured using Trypan dye. (I) Bulk PBMCs (n = 6, PBMCs from 2 donors) were treated with 10 µM SCD1i and/or 20 µM FADS2i immediately following EBV infection, and CD19 + B cell <t>proliferation</t> was based on <t>CellTrace</t> Violet dilution over time. (J) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 2.5 μg/mL CpG and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. (K) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 5 ng/mL CD40L+20 ng/mL IL-4 and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. Statistical significance for pairwise comparisons determined using a Tukey’s post-hoc test or Dunnett’s post-hoc test (panels B & D) (* p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005).
    Fluorescent Proliferation Tracking Dye Celltrace Violet, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fluorescent proliferation tracking dye celltrace violet/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    fluorescent proliferation tracking dye celltrace violet - by Bioz Stars, 2026-05
    90/100 stars

    Images

    1) Product Images from "Fatty acid desaturases link cell metabolism pathways to promote proliferation of Epstein-Barr virus-infected B cells"

    Article Title: Fatty acid desaturases link cell metabolism pathways to promote proliferation of Epstein-Barr virus-infected B cells

    Journal: PLOS Pathogens

    doi: 10.1371/journal.ppat.1012685

    (A-B) LCL growth in the presence of indicated doses of A939572 (SCD1i) (n = 4, LCLs from 4 donors). Growth was measured using Cell Titer Glo. (C-D) LCL growth in the presence of SC-26196 (FADS2i) (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (E) LCL growth in the presence of 10 μM SCD1i, 20 μM SC-26196 FADS2i, or both inhibitors (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (F) Representative dot plots, gated on live and dead single cells, showing anti-BrdU (FITC) versus total DNA (7-AAD) to measure the number of cells in each stage of the cell cycle at 48 hours post treatment. (G) DMSO-normalized relative percentage of single cells in S phase after 48 hours of drug treatment (n = 3, LCLs from 3 donors). (H) DMSO-normalized relative live cell percentage and number after 72 hours of treatment with indicated drugs (n = 4, from 4 donors). Cell number measured using Trypan dye. (I) Bulk PBMCs (n = 6, PBMCs from 2 donors) were treated with 10 µM SCD1i and/or 20 µM FADS2i immediately following EBV infection, and CD19 + B cell proliferation was based on CellTrace Violet dilution over time. (J) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 2.5 μg/mL CpG and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. (K) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 5 ng/mL CD40L+20 ng/mL IL-4 and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. Statistical significance for pairwise comparisons determined using a Tukey’s post-hoc test or Dunnett’s post-hoc test (panels B & D) (* p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005).
    Figure Legend Snippet: (A-B) LCL growth in the presence of indicated doses of A939572 (SCD1i) (n = 4, LCLs from 4 donors). Growth was measured using Cell Titer Glo. (C-D) LCL growth in the presence of SC-26196 (FADS2i) (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (E) LCL growth in the presence of 10 μM SCD1i, 20 μM SC-26196 FADS2i, or both inhibitors (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (F) Representative dot plots, gated on live and dead single cells, showing anti-BrdU (FITC) versus total DNA (7-AAD) to measure the number of cells in each stage of the cell cycle at 48 hours post treatment. (G) DMSO-normalized relative percentage of single cells in S phase after 48 hours of drug treatment (n = 3, LCLs from 3 donors). (H) DMSO-normalized relative live cell percentage and number after 72 hours of treatment with indicated drugs (n = 4, from 4 donors). Cell number measured using Trypan dye. (I) Bulk PBMCs (n = 6, PBMCs from 2 donors) were treated with 10 µM SCD1i and/or 20 µM FADS2i immediately following EBV infection, and CD19 + B cell proliferation was based on CellTrace Violet dilution over time. (J) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 2.5 μg/mL CpG and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. (K) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 5 ng/mL CD40L+20 ng/mL IL-4 and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. Statistical significance for pairwise comparisons determined using a Tukey’s post-hoc test or Dunnett’s post-hoc test (panels B & D) (* p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005).

    Techniques Used: Infection



    Similar Products

    fluorescent proliferation tracking dye celltrace violet  (Thermo Fisher)
    90
    Thermo Fisher fluorescent proliferation tracking dye celltrace violet
    (A-B) LCL growth in the presence of indicated doses of A939572 (SCD1i) (n = 4, LCLs from 4 donors). Growth was measured using Cell Titer Glo. (C-D) LCL growth in the presence of SC-26196 (FADS2i) (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (E) LCL growth in the presence of 10 μM SCD1i, 20 μM SC-26196 FADS2i, or both inhibitors (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (F) Representative dot plots, gated on live and dead single cells, showing anti-BrdU (FITC) versus total DNA (7-AAD) to measure the number of cells in each stage of the cell cycle at 48 hours post treatment. (G) DMSO-normalized relative percentage of single cells in S phase after 48 hours of drug treatment (n = 3, LCLs from 3 donors). (H) DMSO-normalized relative live cell percentage and number after 72 hours of treatment with indicated drugs (n = 4, from 4 donors). Cell number measured using Trypan dye. (I) Bulk PBMCs (n = 6, PBMCs from 2 donors) were treated with 10 µM SCD1i and/or 20 µM FADS2i immediately following EBV infection, and CD19 + B cell <t>proliferation</t> was based on <t>CellTrace</t> Violet dilution over time. (J) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 2.5 μg/mL CpG and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. (K) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 5 ng/mL CD40L+20 ng/mL IL-4 and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. Statistical significance for pairwise comparisons determined using a Tukey’s post-hoc test or Dunnett’s post-hoc test (panels B & D) (* p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005).
    Fluorescent Proliferation Tracking Dye Celltrace Violet, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/fluorescent proliferation tracking dye celltrace violet/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    fluorescent proliferation tracking dye celltrace violet - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A-B) LCL growth in the presence of indicated doses of A939572 (SCD1i) (n = 4, LCLs from 4 donors). Growth was measured using Cell Titer Glo. (C-D) LCL growth in the presence of SC-26196 (FADS2i) (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (E) LCL growth in the presence of 10 μM SCD1i, 20 μM SC-26196 FADS2i, or both inhibitors (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (F) Representative dot plots, gated on live and dead single cells, showing anti-BrdU (FITC) versus total DNA (7-AAD) to measure the number of cells in each stage of the cell cycle at 48 hours post treatment. (G) DMSO-normalized relative percentage of single cells in S phase after 48 hours of drug treatment (n = 3, LCLs from 3 donors). (H) DMSO-normalized relative live cell percentage and number after 72 hours of treatment with indicated drugs (n = 4, from 4 donors). Cell number measured using Trypan dye. (I) Bulk PBMCs (n = 6, PBMCs from 2 donors) were treated with 10 µM SCD1i and/or 20 µM FADS2i immediately following EBV infection, and CD19 + B cell proliferation was based on CellTrace Violet dilution over time. (J) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 2.5 μg/mL CpG and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. (K) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 5 ng/mL CD40L+20 ng/mL IL-4 and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. Statistical significance for pairwise comparisons determined using a Tukey’s post-hoc test or Dunnett’s post-hoc test (panels B & D) (* p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005).

    Journal: PLOS Pathogens

    Article Title: Fatty acid desaturases link cell metabolism pathways to promote proliferation of Epstein-Barr virus-infected B cells

    doi: 10.1371/journal.ppat.1012685

    Figure Lengend Snippet: (A-B) LCL growth in the presence of indicated doses of A939572 (SCD1i) (n = 4, LCLs from 4 donors). Growth was measured using Cell Titer Glo. (C-D) LCL growth in the presence of SC-26196 (FADS2i) (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (E) LCL growth in the presence of 10 μM SCD1i, 20 μM SC-26196 FADS2i, or both inhibitors (n = 4, LCLs from 4 donors). Growth was measured as in A-B. (F) Representative dot plots, gated on live and dead single cells, showing anti-BrdU (FITC) versus total DNA (7-AAD) to measure the number of cells in each stage of the cell cycle at 48 hours post treatment. (G) DMSO-normalized relative percentage of single cells in S phase after 48 hours of drug treatment (n = 3, LCLs from 3 donors). (H) DMSO-normalized relative live cell percentage and number after 72 hours of treatment with indicated drugs (n = 4, from 4 donors). Cell number measured using Trypan dye. (I) Bulk PBMCs (n = 6, PBMCs from 2 donors) were treated with 10 µM SCD1i and/or 20 µM FADS2i immediately following EBV infection, and CD19 + B cell proliferation was based on CellTrace Violet dilution over time. (J) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 2.5 μg/mL CpG and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. (K) PBMCs (n = 4, PBMCs from 2 donors) were stimulated with 5 ng/mL CD40L+20 ng/mL IL-4 and treated with 10 µM SCD1i and/or 20 µM FADS2i. CD19 + B cell proliferation was assessed based on Cell Trace Violet dilution after five days. Statistical significance for pairwise comparisons determined using a Tukey’s post-hoc test or Dunnett’s post-hoc test (panels B & D) (* p < 0.05, **p < 0.005, ***p < 0.0005, ****p < 0.00005).

    Article Snippet: To track proliferation in early EBV-infected B cells, cells were stained with the fluorescent proliferation tracking dye CellTrace Violet (ThermoFisher, Cat# C34557 ).

    Techniques: Infection